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In this paper, we discuss and critically analyse pre-hospital
management of acute myocardial infarction (AMI). It is
clear from several large studies that rapid diagnosis and
application of thrombolysis reduces morbidity and
mortality rates. Strategies that improve time to treatment in
the pre-hospital setting are therefore of fundamental
importance in the management of this fatal disease. The
advantage of 12 lead electrocardiography use by
paramedics to diagnose AMI and reduce time to treatment
is discussed. Moreover, paramedic application of
thrombolysis in the pre-hospital environment is examined.
Several studies conducted worldwide support the notion
that ambulance services can play a role in minimising time
to treatment for patients with AMI. The contribution of early
intervention by paramedics trained in critical care is
potentially considerable, particularly in the important chain
of survival that is often initiated by pre-hospital
intervention.
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T
he effectiveness of early thrombolysis in the
management of acute myocardial infarction
(AMI) is well established, particularly with
regard to its positive effect on mortality rates.
However, several factors delay the time to
receiving reperfusion therapy. Of particular
interest are factors that can be directly influ-
enced by paramedics. This paper will critically
analyse advantages and disadvantages of 12 lead
electrocardiography and thrombolysis for diag-
nosis and treatment of AMI pre-hospital.
PATHOPHYSIOLOGY OF ACUTE
MYOCARDIAL INFARCTION
AMI is characterised by myocardial tissue
damage resulting from substantial intervals of
ischaemia, caused by an acute thrombus occlud-
ing or narrowing an atherosclerotic artery.
Platelet aggregation and activated coagulation
increase degeneration of the vessel lumen, while
platelet function altered by endothelial changes
in the atherosclerotic plaque also contributes to
thrombogenesis.1–4
PREVALENCE
Approximately 12 million lives are lost annually
from the effects of cardiovascular disease (World
Health Organisation), making it universally the
major cause of death, responsible for 50% and
30% of all deaths in developed and developing
countries, respectively. Moreover, 50% of AMI
patients die prior to reaching hospital. Of those
who survive, 50% are re-hospitalised within a
year and 5–10% suffer a fatal attack.5
TREATMENT
Reperfusion therapy
A reduction in cardiac function caused by
irreversible necrosis of the myocardium can
result from complete occlusion of a cardiac
vessel. The resultant ischaemia is reversible if
treated within 3–6 hours. Therapy aiding reper-
fusion of ischaemic cardiac muscle within this
critical time period can reduce the extent and
severity of damage thereby reducing mortality
and morbidity.6 7 Reperfusion is possible by a
variety of procedures including, thrombolysis,
percutaneous transluminal coronary angioplasty
(PTCA), and coronary artery bypass graft surgery
(CABG). Choice of procedure is determined by
patient condition, location and extent of the
ischaemia, staff and equipment resources, hos-
pital protocols, and the personal bias of the
attending physician. Regardless of the form,
rapid diagnosis and intervention of the ischaemic
event is crucial for effective early management.1–7
Several trials conducted in recent years indi-
cate that appropriate application of thrombolysis
significantly improves mortality rates; treatment
within 6 hours of the onset of pain leads to an
overall reduction in mortality of between 26 and
65 per 1000 patients, and this has been exten-
sively documented.5 7 Additionally, availability of
the therapy within hospital emergency depart-
ments (EDs) makes thrombolysis a front line
therapy for treatment of AMI.
Primary angioplasty
Primary PTCA performed punctually by skilled
medical practitioners is the more beneficial
therapy in certain circumstances, having a
number of advantages over thrombolysis, includ-
ing lower risk of haemorrhagic incident and
improved conditions for coronary assessment.8 9
Therefore, when time to in hospital treatment is
short, such as occurs in a metropolitan area,
PTCA should be the treatment of choice.
Evidence also suggests that angioplasty after
short acting thrombolytic therapy is the most
beneficial, improving outcomes for AMI patients,
particularly if there is a delay of more than
Abbreviations: AMI, acute myocardial infarction; CABG,
coronary artery bypass graft surgery; CAPTIM,
Comparison of Angioplasty and Prehospital Thrombolysis
In Acute Myocardial Infarction; ECG, electrocardiogram;
ED, emergency department; GP, general practitioner;
PTCA, percutaneous transluminal coronary angioplasty
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1 hour before treatment of angioplasty, a common occur-
rence, particularly in rural areas.9
However, the cost of providing experienced staff and
appropriate facilities make PTCA disadvantageous.5 9 In fact,
in many pre-hospital environments and peripheral hospitals,
angioplasty is unavailable and thrombolytic agents remain
the most available and most effective intervention. This paper
will therefore focus on the pre-hospital application of
thrombolysis and its affect on survival post AMI.
Thrombolytic agents
AMI is the result of an occlusion to a coronary vessel or
vessels. Thrombolytic therapy is aimed at lysis of the
occlusion, removal of the obstruction, and restoration of
blood flow to the ischaemic myocardium.1–5 Thrombolytic
agents eliminate the obstruction by activating the enzyme,
plasmin, which in turn denatures fibrin, a protein binding
the fibrous strands in blood clots.
Several different thrombolytic agents are available includ-
ing streptokinase, tissue plasminogen activator alteplase,
anistreplase, and urokinase. In the pre-hospital setting,
newer more effective derivatives of alteplase, including
reteplase and tenecteplase, are preferred, because they can
be administered by single injection rather than infusion.10
Moreover, with the newer drugs, the dosing pattern is
standard irrespective of the body weight of the patient,
making use simple in the pre-hospital setting.11 These factors
are important as they lead to decreased time to treatment,
which is the most critical factor in reducing mortality rates.
The pharmacological action of thrombolytic agents is not
limited to the site of the thrombus alone; activity extends
throughout the vascular system, reducing thrombus forma-
tion and improving cerebral reperfusion.12–14 However, a small
percentage of those receiving therapy suffer a haemorrhagic
incident. Benefit versus risk therefore needs to be carefully
assessed on an individual basis.13 14
Early reperfusion
Regardless of the agent used, thrombolysis is the therapy of
choice for the treatment of AMI. Large scale trials provide
evidence that early reperfusion therapy is extremely effective,
with the greatest benefit gained from therapy within the first
3 hours. Mortality rates can be lowered by as much as 6.5% if
treatment is given within the first hour, falling to 3.7% if
within 2 hours and 2.6% after 6 hours.7 Beyond 12 hours,
thrombolytic therapy is no longer effective.
In the large TIMI-II trial, it was shown that for every hour
that thrombolytic therapy is delayed, fatality rates rise 1%,
with the most beneficial time being within the first hour after
the onset of symptoms.15 16 In fact between 30% and 50% of
patients with AMI fail to reperfuse when treatment is delayed
for 90 minutes or more.17 The prognosis of these patients is
reduced, irrespective of age, sex, area of the myocardium
involved, or the thrombolytic agent used.5 In these cases
percutaneous coronary intervention is used as a mode of
"rescue".17
Thrombolytic therapy delays
Factors that negatively impact on time to reperfusion therapy
are either patient or treatment related, and include delays
caused by pre-hospital evaluation or treatment delays in the
ED.18
Public education and perception of signs and symptoms of
AMI are critical in reducing mortality rates. Remarkably, in
industrially developed nations, only 50% of those with
symptoms of AMI access the ambulance service. This figure
is staggering considering the plethora of data indicating that
ambulance assistance leads to a shorter time to definitive
care because baseline examinations, history taking, and
early interventions are initiated by pre-hospital ambulance
officers.19 20 While patient delay is a contributing factor, there
are delays that can be directly affected by paramedics. One
intervention that can be extremely effective in reducing time
to treatment is 12 lead electrocardiography performed prior to
arrival at the hospital.
12 lead electrocardiography
Acute coronary syndromes encompass a heterogenous group
of patients with different clinical presentations, and differ-
ences in the extent and severity of underlying coronary
atherosclerosis and degree of risk of progression to AMI.21 For
each patient, it is necessary for the pre-hospital practitioner
to make rapid individual treatment decisions based on the
history, examination, facilities and diagnostic equipment
available, and transfer time to the nearest appropriate
hospital. The recognition of AMI in the pre-hospital environ-
ment can be a difficult task. For example, silent AMI, in older
patients, women, diabetics, and those taking non-steroidal
analgesics, presents with breathing difficulty, heart failure,
and neurological impairment as opposed to the more classic
radiating or non-radiating retrosternal chest pain.6 7
Electrocardiography is the key diagnostic tool to determine
eligibility for acute reperfusion interventions. Because elec-
trocardiography machines are portable and easy to use, there
has been growing interest in their use in the pre-hospital
setting. Although paramedics can obtain 12 lead electro-
cardiography readings reliably, pre-hospital electrocardiogra-
phy is not routinely performed in many countries.23 A study
by Canto et al using a database of 275 000 from the National
Registry of Myocardial Infarction showed that only 5% of
patients receive field electrocardiography.27
Where ambulance service paramedics do use 12 lead
electrocardiography to assist with early diagnosis of AMI,
they achieve this in one of two ways. Either the 12 lead
electrocardiogram (ECG) is transmitted to a doctor who
makes a diagnosis (and may communicate this diagnosis
back to the ambulance crew), or alternatively, ambulance
paramedics are trained to interpret the ECG themselves.
Transmission of an ECG requires technology at both ends of
the transmission, a fault free line, the immediate availability
of a senior doctor to make the diagnosis, and a system for
communicating the diagnosis back to the ambulance crew.
This system has a one in five chance of failure due to
communication delays. Furthermore, such a system requires
expensive, well maintained technology.6 These problems are
avoided if the paramedic can interpret the 12 lead ECG and
recognise ST segment elevation.
Concerns have been raised over the accuracy and feasibility
of 12 lead electrocardiography performance in the pre-
hospital environment as well as the ability of paramedics to
perform checklists safely and therapeutically.28 The successful
interpretation of the 12 lead electrocardiography by trained
paramedics has now been documented in several studies.22–33
For example, a 5 year study in Canada showed that
paramedics can accurately identify patients who would have
the greatest likelihood of benefiting from early, aggressive
thrombolytic therapy.33 Moreover, a study in the UK
compared paramedics and cardiologists;22 paramedics
received two days intensive training in interpretation of a
12 lead ECG followed by consolidation in the field, after
which time it was demonstrated that there was no significant
difference between the two groups in recognition of ST
segment elevation. As a result of this study, the need to
transmit 12 lead electrocardiography results to hospitals for
interpretation was negated.22 A multitude of evidence now
demonstrates beyond doubt that well trained paramedics can
efficiently use 12 lead electrocardiography to provide early
diagnosis and reduce delays.
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The only controversy that remains is whether time to
treatment is significantly affected when patients receive a 12
lead electrocardiography diagnostic intervention pre-hospital.
While some authors express concerns regarding delays to
treatment time associated with 12 lead electrocardiography
use by paramedics, four independent studies have shown
that while there may be an increase in time at the scene of
between 4 and 10 minutes, on average the overall time to
treatment is decreased.29–32 Generally, the use of pre-hospital
12 lead electrocardiography appears to provide a multitude of
benefits including deceased mortality, increased likelihood of
receiving thrombolysis, increased likelihood of angioplasty,
increased likelihood of CABG, and most importantly,
decreased time to treatment.27
Pre-hospital reperfusion
Given that early thrombolytic therapy is highly desirable and
that appropriately trained paramedics can effectively inter-
pret 12 lead electrocardiography readings, the question then
becomes: can appropriately skilled paramedics administer
thrombolytic therapy in the pre-hospital setting, to further
improve the chain of survival for patients with AMI? Several
trials have been conducted to answer this question. Some
trials have involved administration of thrombolytic agents by
medical practitioners in the pre-hospital setting and others
have compared the use of thrombolysis in the pre-hospital
setting by paramedics and medical practitioners. In general,
the outcomes were positive, and showed reduced mortality
and reduced time to reperfusion as a result of early
thrombolysis administration. In most cases, hospital delays
were reduced by the transmission of 12 lead electrocardio-
graphy and or direct admission.26 34–38
Support for pre-hospital application of thrombolytic
therapy has been provided by a study in Scotland, which
showed that general practitioners (GPs) providing pre-
hospital therapy affected mortality rates positively and that
these continued to improve after discharge from hospital.35
This study demonstrated that thrombolytic therapy can be
safely administered outside of the hospital setting, can reduce
treatment delays, and has significant beneficial outcomes.
A more recent analysis of mortality rates and pre-hospital
thrombolysis administered by paramedics, intensive care
paramedics and GPs showed the clear benefits of pre-hospital
thrombolysis. A meta-analysis of six major randomised trials
conducted by the American Heart Association, involving
more than 6000 patients, demonstrated that thrombolytic
treatment decreased time to treatment from the onset of
symptoms by an average of 58 minutes (an average of
33 minutes in the urban areas and 130 minutes in rural
areas). This led to a 17% reduction in relative risk in hospital
mortality and an absolute risk reduction of 2%. which can be
converted into one life saved per 62 patients treated in the
pre-hospital setting.34 This study also clearly demonstrated
that neither drug type nor level of medical practitioner
affected outcome.34 Similarly a study in Victoria, Australia,
showed that pre-hospital thrombolysis saves lives; calling for
an ambulance rather than the GP has the greatest potential to
save lives.20
Despite this and as a result of the Myocardial Infarct and
Triage Intervention trial, the European Society of Cardiology
and the European resuscitation council recommended pre-
hospital thrombolysis be administered when times from the
arrival at scene to hospital door are expected to exceed
30 minutes.26 Even if physicians administer thrombolytic agents
more effectively than appropriately trained paramedics,17 there
remains no doubt that delaying reperfusion of an ischaemic
myocardium is fatal or affects quality of life. Thus, it may be
time to advance the level of care given by ambulance service
paramedics so that delays can be minimised.39
While thrombolysis administration by paramedics is
advocated,39 it is agreed that the administration of agents
with fibrinolytic properties, particularly in uncontrolled
environments, is a considerable responsibility. Although
thrombolysis is an effective treatment strategy for both
AMI and pulmonary embolism, clinical experience of this
therapy, performed during resuscitation, has been limited
owing to the anticipated risk of severe bleeding complica-
tions. The Thrombolysis in Cardiac Arrest study, one of the
largest randomised, double blind, placebo controlled trials, is
planned to assess the efficacy and safety of pre-hospital
thrombolytic therapy in cardiac arrest of presumed cardiac
origin.40 The results of this study should clarify these issues
and provide a clear framework for future therapeutic
strategies.
CONCLUSION
Pre-hospital cardiac arrest has been associated with a very
poor prognosis. AMI and massive pulmonary embolism are
the underlying causes of out-of-hospital cardiac arrest in 50–
70% of patients. Reducing the event to definitive treatment
time should therefore be a priority, achieved through a
multimodal strategy. The issues that need to be addressed
include: education of the general public, access to emergency
and healthcare systems, ambulance operations, paramedic
training and education, and the interaction between in
hospital and pre-hospital management.
Thrombolysis is an effective therapy that can result in
reperfusion of ischaemic myocardium. The benefits of
therapy are directly proportional to time from symptoms to
administration, with most positive effects seen from admin-
istration within the first hour after onset of symptoms. There
is evidence that supports the view that pre-hospital admin-
istration has benefits that clearly outweigh the risks
particularly in areas of extended transport.
The polarised debate over the advantages of primary
angioplasty verses thrombolysis has negatively impacted on
implementation of thrombolysis for treatment of acute MI. In
2003,41 the benefits of angioplasty over thrombolysis were
championed, using data from the Comparison of Angioplasty
and Prehospital Thrombolysis. In Acute Myocardial
Infarction (CAPTIM) trial.9 As a result, thrombolysis was
not considered the ‘‘standard treatment’’ for acute MI.
Moreover, a 3 hour delay to administration of thrombolysis
in favour of transportation to an intervention centre was
recommended.41 This position was challenged by Lamfers and
Verheught,42 who pointed out that the CAPTIM trial data in
fact negates the benefits of angioplasty over thrombolysis if
all preparation, age, and time issues are taken into account.
In fact, the CAPTIM trial strongly advocates the use of pre-
hospital triage and early treatment.
Regardless of the position held in this argument, it is clear
that thrombolysis remains a highly effective treatment
strategy, particularly in areas that do not have ready access
to a system of well developed intervention centres. It is in
these cases particularly that treatment delays result in
definitive care being compromised well beyond that useful
for reperfusing compromised myocardial tissue.43 44
For those who have worked in the pre-hospital field, it is
clear that the rapid identification and transport of patients
with AMI has been and should be the focus of patient
management. The data from a number of studies indicate
that, at the very least, paramedics should be performing 12
lead electrocardiography in the field. This practice should be
augmented by direct admission to an appropriate facility
rather than standard ED admission.
With the advent of improved paramedic education and
training and the release of new generation thrombolytic
agents, more definitive care by trained paramedics is
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advocated. The UK has become the frontrunner in the
introduction of prehospital thrombolysis and 12 lead electro-
cardiography for paramedics, with active programmes under-
way across a number of services. The USA has also begun the
implementation of 12 lead electrocardiography and throm-
bolysis in isolated services. Australia has one state service
(the rural ambulance service of Victoria) conducting a trial
for the effectiveness of pre hospital thrombolysis. Two other
Australian states, New South Wales and Queensland,
currently allow use of 12 lead electrocardiography by high
level paramedics and are implementing trials of the
technique by all paramedics in the field.
While the administration of pre-hospital thrombolysis to
people with AMI remains a contentious issue, particularly if
performed by paramedics, what cannot be argued is that
early thrombolytic intervention reduces mortality and mor-
bidity rates. Delays to this intervention are the greatest
problem facing those with AMI; every minute of delay results
in loss of expected longevity. A recent study in Portugal has
again shown that pre-hospital intervention vastly improves
outcome for AMI patients, particularly the elderly.45
The ambulance system and paramedics can directly and
indirectly reduce these delays, and evidence to support
implementation of advanced clinical practices in the field is
currently being sought locally.
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